Publications in collaboration with researchers from Hospital Universitario de Salamanca (10)

2022

  1. The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 41, Núm. 2, pp. 126-135

  2. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

2021

  1. The 18F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 40, Núm. 3, pp. 149-154

2020

  1. A novel Col4A1 mutation: recognizing an uncommon cause of stroke

    European Journal of Neurology

  2. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

    Targeted Oncology, Vol. 15, Núm. 5, pp. 613-622

  3. FDG PET/CT in colorectal cancer

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 39, Núm. 1, pp. 57-66

2018

  1. Procedimientos recomendados para el control de calidad de IMRTen tomoterapia

    Revista de Física Médica, Vol. 19, Núm. 2, pp. 73-102

2016

  1. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272]

    Reports of Practical Oncology and Radiotherapy

  2. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

    Reports of Practical Oncology and Radiotherapy, Vol. 20, Núm. 4, pp. 259-272